Why Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Down 9.30%
As of Wednesday, July 01, Oramed Pharmaceuticals Inc.’s ORMP share price has dipped by 9.30%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Commentary & Analysis
Why Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Up 6.16%
As of Thursday, June 25, Oramed Pharmaceuticals Inc.’s ORMP share price has surged by 6.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Up 17.21%
As of Thursday, June 25, Oramed Pharmaceuticals Inc.’s ORMP share price has surged by 17.21%, which has investors questioning if this is right time to sell.Tudor Pop
Why Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Down 5.78%
As of Tuesday, June 02, Oramed Pharmaceuticals Inc.’s ORMP share price has dipped by 5.78%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Oramed Pharmaceuticals Inc.’s (ORMP) Stock Is Down 6.36%
As of Monday, May 18, Oramed Pharmaceuticals Inc.’s ORMP share price has dipped by 6.36%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $166.6 | $579.1 | 26% |
|
| Shares Out (Mil) | 42.0 | 43.0 | 44% |
|
| Institutional Ownership | 56.1% | 84.3% | 38% |
|
| Float (Mil) | 31.6 | 46.8 | 37% |
|
| Beta | 1.26 | 0.62 | 73% |
|
| Avg Daily Volume (000s) | 148 | 285 | 40% |
|
| Price Change (52-week) |
91.1% | 63.8% | 90% |
|
| Growth | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (5.8%) | 6.7% | 8% |
|
| Net Income (5yr) | 37.3% | (1.4%) | 89% |
|
| EPS (5yr) | 31.4% | 14.9% | 82 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.0%) | (14.9%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | $110 | ($11) | 62% |
|
| EPS (TTM) | $2.645 | ($0.500) | 76% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($6) | 21% |
|
| Net Cash Flow (TTM) (Mil) | ($61) | $4 | 18% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $7 | 15% |
|
| Enterprise Value (Q1) (Mil) | $64 | $522 | 18% |
|
| Valuation | ORMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.70 | 2.73 | 14% |
|
| P/E | 1.6 | 20.5 | 1% |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | 0.1 | 1.2 | 1% |
|
| Ratios | ORMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | 52.8% | (24.6%) | 99% |
|
| ROE | 58.0% | (19.7%) | 93% |
|
| Liabilities to Assets | 11.4% | 35.5% | 7% |
|
| F-Score | 3 | 3 | 19% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Fundamental Rule of Thumb Screen
Factors: Value
An old value screen combining the P/E ratio, dividend yield, and an adjusted return on equity that's still applicable in today's market.
| Performance Since Inception: | 6.6% |
| +/- S&P 500: | -0.9 |
